

In the name of God

Taher Entezari-Maleki

Multivitamins

- ▶ Evidence suggested a possible small benefit for
- ▶ Cancer Any cancer incidence: OR, 0.93 (95% CI, 0.87-0.99); but small to no benefit for all-cause mortality or CVD
- ▶ Harm
- ▶ Cataract, small increase of rash and epixtaxis

Beta carotene (Vitamin A)

- ▶ Paradoxical
- ▶ Small increase of CV mortality : OR, 1.10 (95% CI, 1.02-1.19); 5 RCTs (n = 95 506);
- ▶ Harm
- ▶ The most substantial serious harms are the paradoxical harms of increased all-cause mortality, CVD mortality, and lung cancer
- ▶ Trials generally showed no statistically significant findings for other adverse events other than hypercarotenoderma and GI symptoms
- ▶ Two cohort studies in women found an elevated but not statistically significantly increased risk of hip fracture

Vitamin E

- ▶ Most evidence indicated that vitamin E had no benefit for mortality, CVD
- ▶ Harm
 - ▶ Hemorrhagic stroke: low for increased risk
 - ▶ Cataracts, hospitalization from pneumonia, other nonserious: low for no increased risk

Vitamin D (with or without calcium)

- ▶ No benefit on CVD
- ▶ 32 RCTs (n = 123 140 observations)
- ▶ CVD events: 1.00 (95% CI, 0.95-1.05); 7 RCTs (n = 74 925)
- ▶ Harm
- ▶ Both trial and cohort evidence suggested an increased risk of kidney stones with 1000 IU/d or more of vitamin D over ≥ 7 y
- ▶ Most evidence supported no increased risk of GI-related symptoms

Calcium

- ▶ Most evidence indicated no benefit for mortality, CVD,
- ▶ All-cause mortality: 1.05 (95% CI, 0.92-1.21; 6 RCTs [n = 8394])
- ▶ CVD events: 1.11 (95% CI, 0.90-1.36; 4 RCTs [n = 4076])
- ▶ Harm
- ▶ Findings suggested an increased risk of constipation and GI symptoms and possibly kidney stones

[Create Free Account or](#)[Clinical Topics](#)[Latest In Cardiology](#)[Education and Meetings](#)[Tools and Practice Support](#)[Log in to MyACC](#)

Micronutrient Supplementation to Reduce Cardiovascular Risk

Dec 05, 2022

Share via:  [Print](#)

Font Size A A A

Authors: An P, Wan S, Luo Y, et al.

Citation: Micronutrient Supplementation to Reduce Cardiovascular Risk. *J Am Coll Cardiol* 2022;80:2269-2285. [↗](#)

Summary By: Elizabeth A. Jackson, MD, FACC

Similar Articles from ACC.org

Mar 06, 2023 | Journal Scan
[Inflammation and Cholesterol as Predictors of CV Events With Statin Therapy](#)

Mar 06, 2023 | Clinical Trial
[FREEDOM COVID Anticoagulation Strategy Randomized Trial](#)

Mar 06, 2023 | Clinical Trial
[Macitentan/Tadalafil Fixed-Dose Combination in Pulmonary Arterial Hypertension](#)

Mar 06, 2023 | ACC News Story

RCTs


The background of the slide is white, with abstract purple geometric shapes on the right side. These shapes include overlapping triangles and polygons in various shades of purple, ranging from light lavender to deep, dark purple. The shapes create a modern, layered effect on the right edge of the slide.

Antioxidant Micronutrient		Randomized Controlled Trials on CVD Risk Factors		Blood Pressure		Blood Lipid				Blood Glucose		
		Median Dose [Range]	Median Duration [Range], Month	Systolic Blood Pressure	Diastolic Blood Pressure	Total Cholesterol	Low-Density Lipoprotein Cholesterol	High-Density Lipoprotein Cholesterol	Triglyceride	Hemoglobin A1c	Fasting Blood Glucose	Fasting Blood Insulin
Fatty Acid	n-3	2 g/d [0.28-9.50 g/d]	3 [0.69-60]	•	•	•	•	▲	▼	•	•	•
	n-6	4.25 g/d [1-20 g/d]	2.07 [0.69-24]	•	•	▼	▼	▲	•		•	
	n-9		1.38 [0.46-1.84]			•	•	•	▲			
Amino Acid	L-arginine	6 g/d [1.3-30 g/d]	1.50 [0.23-30]	▼	▼	•	•	•	•	•	▼	▼
	L-citrulline	6 g/d [2-6 g/d]	1.15 [0.23-1.84]	▼	▼	•	•	•	•			
Vitamin	Folic Acid	5 mg [0.25-15 mg]	1.84 [0.23-53.85]	▼	▼	▼	▼	•	▼	•	▼	▼
	Vitamin C	500 mg/d [50-3,000 mg/d]	1.84 [0.33-60]	•	•	•	•	▲	•	•	•	•
	Vitamin C + E	1,400 mg/d [300-1,400 mg/d]	3 [1.84-5.52]	•	•	•	•	•	•			
	Vitamin D	3,410 IU/d [40-120,000 IU/d]	3 [1.38-84]	•	•	•	•	•	•	▼	▼	•
	Vitamin E	400 mg/d [3-1,800 mg/d]	2 [0.69-72]	•	•	•	•	•	•	▼	•	•

Direction	Cardiometabolic Health	Evidence Quality
▼ Decrease	Benefit	High Quality
▲ Increase	Benefit	Moderate Quality
▲ Increase	Harm	Low Quality
• Unchanged	Neutral	Very Low Quality

		Randomized Controlled Trials on CVD Risk Factors		Blood Pressure		Blood Lipid				Blood Glucose		
		Median Dose [Range]	Median Duration [Range], Month	Systolic Blood Pressure	Diastolic Blood Pressure	Total Cholesterol	Low-Density Lipoprotein Cholesterol	High-Density Lipoprotein Cholesterol	Triglyceride	Hemoglobin A1c	Fasting Blood Glucose	Fasting Blood Insulin
Mineral	Magnesium	400 mg/d [200-729 mg/d]	2.76 [1-6]	▼	▼	●	●	▲	▼	●	●	●
	Selenium	200 µg/d [100-960 µg/d]	2.76 [1.38-6]	●	●	●	●	●	●	●	●	●
	Zinc	30 mg/d [5-200 mg/d]	2 [0.92-12]	●	●	▼	●	●	▼	▼	▼	▼
Antioxidant Supplement	α-Lipoic Acid	600 mg/d [100-2,400 mg/d]	2.96 [1.84-16.57]	▼	▼	●	●	▲	●	●	●	●
	β-carotene											
	Coenzyme Q10	300 mg/d [60-1,200 mg/d]	2.76 [0.56- 6]	▼	●	●	●	●	▼	▼	●	●
	Lycopene	15 mg/d [5-30 mg/d]	2 [1.38-6]	▼	●	●	●	●	●			
	Melatonin	5 mg/d [1-24 mg/d]	1.84 [0.46-12]	●	●	▼	●	●	●		●	●

		Randomized Controlled Trials on CVD Risk Factors		Blood Pressure		Blood Lipid				Blood Glucose		
		Median Dose [Range]	Median Duration [Range], Month	Systolic Blood Pressure	Diastolic Blood Pressure	Total Cholesterol	Low-Density Lipoprotein Cholesterol	High-Density Lipoprotein Cholesterol	Triglyceride	Hemoglobin A1c	Fasting Blood Glucose	Fasting Blood Insulin
Polyphenol	Anthocyanin	160 mg/d [1.65-1,024 mg/d]	1.84 [0.46-6]	○	○	▼	▼	▲	▼	○	▼	○
	Catechin	456 mg/d [20-1,344 mg/d]	2.76 [0.46-12]	○	○	▼	○	○	○	▼	▼	○
	Curcumin	500 mg/d [80-2,400 mg/d]	2.76 [2.38-5.52]	▼	○	○	○	▲	○	▼	▼	▼
	Flavanol	805 mg/d [6.5-20,000 mg/d]	1.18 [0.46-11.97]	▼	○	○	○	▲	○	○	▼	▼
	Flavonoid		4.14 [0.46-12]	○	▼	○	▼	○	○			
	Genistein	54 mg/d [50-90 mg/d]	6 [2.76-36]	▼	▼	▼	▼	○	○		▼	▼
	Hesperidin	500 mg/d [290-500 mg/d]	2.76 [0.69-3]	○	○	○	○	○	○		○	○
	Isoflavone	66 mg/d [10-165 mg/d]	2.76 [0.46-48]	○	○	○	○	○	○	○	○	○
	Quercetin	150 mg/d [50-1,000 mg/d]	1.38 [0.23-2.76]	▼	○	○	○	○	○		○	▼
	Resveratrol	390 mg/d [75-3,000 mg/d]	2.76 [0.92-6.44]	▼	▼	○	○	○	○	○	○	○

- 
- The background of the slide features abstract, overlapping geometric shapes in various shades of purple, ranging from light lavender to deep, dark purple. These shapes are primarily located on the right side and bottom of the slide, creating a modern, layered effect.
- Evidence-based maps summarizing 256 meta-analyses of 884 randomized controlled trials investigating the interventional effects of 27 antioxidant micronutrients on cardiovascular disease risk factors (top) and cardiovascular disease and type 2 diabetes events (bottom)

Micronutrient		Blood Pressure		Blood Lipid				Blood Glucose		
		Systolic Blood Pressure	Diastolic Blood Pressure	Total Cholesterol	Low-Density Lipoprotein Cholesterol	High-Density Lipoprotein Cholesterol	Triglyceride	Hemoglobin A1c	Fasting Blood Glucose	Fasting Blood Insulin
Fatty acid	n-3	●	●	●	●	▲	▼	●	●	●
	n-6	●	●	▼	▼	▲	●		●	
	n-9			●	●	●	▲			
Amino acid	L-arginine	▼	▼	●	●	●	●	●	▼	▼
	L-citrulline	▼	▼	●	●	●	●			
Vitamin	Folic acid	▼	▼	▼	▼	●	▼	●	▼	▼
	Vitamin C	●	●	●	●	▲	●	●	●	●
	Vitamin C+E	●	●	●	●	●	●			
	Vitamin D	●	●	●	●	●	●	▼	▼	●
	Vitamin E	●	●	●	●	●	●	▼	●	●
Mineral	Magnesium	▼	▼	●	●	▲	▼	●	●	●
	Selenium	●	●	●	●	●	●	●	●	●
	Zinc	●	●	▼	●	●	▼	▼	▼	▼
Antioxidant supplement	α-lipoic acid	▼	▼	●	●	▲	●	●	●	●
	Coenzyme Q10	▼	●	●	●	●	▼	▼	●	●
	Lycopene	▼	●	●	●	●	●			
	Melatonin	●	●	▼	●	●	●		●	●
Polyphenol	Anthocyanin	●	●	▼	▼	▲	▼	●	▼	●
	Catechin	●	●	▼	●	●	●	▼	▼	●
	Curcumin	▼	●	●	●	▲	●	▼	▼	▼
	Flavanol	▼	●	●	●	▲	●	●	▼	▼
	Flavonoid	●	▼	●	▼	●	●			
	Genistein	▼	▼	▼	▼	●	●		▼	▼
	Hesperidin	●	●	●	●	●	●		●	●
	Isoflavone	●	●	●	●	●	●	●	●	●
	Quercetin	▼	●	●	●	●	●		●	▼
	Resveratrol	▼	▼	●	●	●	●	●	●	●

Effects of Antioxidant Micronutrient on Cardiovascular Disease and Type 2 Diabetes Events

Micronutrient		All-Cause Mortality	Cardiovascular Disease Mortality	Myocardial Infarction	Stroke	Coronary Heart Disease	Arrhythmia	Type 2 Diabetes
Fatty acid	n-3	•	▼	▼	•	▼	•	•
	n-6							•
Vitamin	Folic acid	•	•	•	▼			
	Vitamin C	•	•	•	•			
	Vitamin D	•	•	•	•	•		
	Vitamin E	•	•	•	•			•
Mineral	Selenium	•	•	•	•	•		
Antioxidant supplement	β-carotene	▲	▲	•	▲			•
	Coenzyme Q10	▼						

Direction Cardiometabolic Health

▼ Decrease Benefit

▲ Increase Benefit

▲ Increase Harm

• Unchanged Neutral

Evidence Quality

High Quality

Moderate Quality

Low Quality

Very Low Quality

An P, et al. J Am Coll Cardiol. 2022;80(24):2269-2285.

Thank you